Aprea's WEE1 Inhibitor Shows Early Promise in Phase 1 Trial
Event summary
- Aprea Therapeutics confirmed a partial response in a patient with PPP2R1A-mutated endometrial cancer treated with APR-1051 at 220 mg once daily.
- The patient achieved a 50% reduction in target lesion size and a reduction in CA-125 levels, with an additional 9.5% reduction confirmed at the second imaging assessment.
- ACESOT-1051 trial has treated 24 patients to date, with two partial responses observed, both in endometrial cancers with PPP2R1A mutations.
- APR-1051 has been generally safe and well-tolerated, with most adverse events reported as Grade 1 or 2.
- Dose escalation is ongoing, with plans to advance to 300 mg once daily in Q2 2026.
The big picture
Aprea Therapeutics' positive early data for APR-1051 underscores the growing focus on biomarker-defined cancers and precision medicine in oncology. The confirmation of a partial response in a Phase 1 trial highlights the potential of WEE1 inhibitors to address significant unmet needs in genetically defined cancers. The company's strategy of differentiated WEE1 inhibition with an improved therapeutic index positions it within the broader trend of developing targeted therapies that minimize effects on healthy cells.
What we're watching
- Clinical Efficacy
- How the confirmed partial response will impact the ongoing development and potential approval of APR-1051.
- Dose Optimization
- The pace at which Aprea can safely escalate the dose to 300 mg once daily and the resulting anti-tumor activity.
- Market Positioning
- Whether Aprea can differentiate APR-1051 as a best-in-class WEE1 inhibitor in the competitive oncology landscape.
Related topics